CA
NZ
UK
AU
IND
US
…
BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for the treatment of molybdenum cofactor deficiency under the NULIBRY brand name; and low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 clinical stage or the treatment of children with achondroplasia and hypochondroplasia. It also develops Encaleret, an oral small molecule, negative allosteric modulator of the calcium sensing receptor, which is in phase 3 clinical study for the treatment of Autosomal Dominant Hypocalcemia Type 1(ADH1) and Chronic Hypoparathyroidism (CHP); BBP-418, an investigational, orally administered, and small molecule therapy that is in phase 3 clinical study for the treatment of LGMD2I; and BBP-812, an investigational adeno-associated virus (AAV) gene therapy for Canavan disease. In addition, the company engages in developing products for mendelian, oncology, and gene therapy diseases. It has license and collaboration agreements with the Bayer Consumer Care AG, Alexion Pharma International Operations Limited Company, Leland Stanford Junior University, and Novartis International Pharmaceutical Ltd. BridgeBio Pharma, Inc. was founded in 2015 and is headquartered in Palo Alto, California.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
BridgeBio Pharma is a clinical-stage biopharma developing precision therapies for genetically defined diseases and oncology across preclinical to late-stage programs. Long-term growth could be supported by successful trial readouts, regulatory approvals, partnerships and milestone payments in high-unmet-need rare diseases, and investors may find the pipeline-driven upside appealing.
The company's biggest risks include high clinical and regulatory failure probability, significant cash burn and reliance on external financing or partners, plus commercialization and reimbursement uncertainty.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -734.99M | -542.19M | -653.25M | -484.65M | -586.45M |
| Minority interest | 8.01M | 7.58M | 10.05M | 3.47M | -23.91M |
| Net income | -729.31M | -535.76M | -643.20M | -493.96M | -639.30M |
| Selling general administrative | 531.23M | 250.93M | 150.59M | 143.19M | 192.21M |
| Selling and marketing expenses | - | 21.50M | - | - | - |
| Gross profit | 473.81M | 218.02M | 6.86M | 74.21M | 66.60M |
| Reconciled depreciation | 5.43M | 6.08M | 6.49M | 6.77M | 5.84M |
| Ebit | -681.88M | -442.90M | -571.96M | -471.87M | -579.75M |
| Ebitda | -672.88M | -436.83M | -565.47M | -353.68M | -539.68M |
| Depreciation and amortization | 9.00M | 6.08M | 6.49M | 118.19M | 40.07M |
| Non operating income net other | - | - | - | 107.99M | 36.96M |
| Operating income | -569.09M | -592.97M | -607.37M | -471.87M | -579.75M |
| Other operating expenses | 1071.16M | 814.88M | 616.67M | 546.09M | 646.35M |
| Interest expense | 53.10M | 99.29M | 81.29M | 80.44M | 46.78M |
| Tax provision | 0.43M | 1.15M | 0.00M | - | - |
| Interest income | 19.85M | 17.25M | 18.04M | 7.54M | 1.13M |
| Net interest income | -158.39M | -82.04M | -63.25M | -72.90M | -45.65M |
| Non recurring | - | - | - | 43.77M | - |
| Income tax expense | 0.56M | 1.15M | 71.51M | 9.31M | 52.84M |
| Total revenue | 502.08M | 221.90M | 9.30M | 77.65M | 69.72M |
| Total operating expenses | 1042.89M | 811.00M | 614.23M | 546.09M | 646.35M |
| Cost of revenue | 28.27M | 3.88M | 2.45M | 3.43M | 3.11M |
| Total other income expense net | -165.90M | 50.78M | -45.88M | -12.78M | -6.71M |
| Net income from continuing ops | -732.94M | -543.35M | -653.25M | -484.65M | -586.45M |
| Net income applicable to common shares | - | - | - | -481.18M | -562.54M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 936.02M | 919.34M | 546.38M | 623.04M | 1012.79M |
| Intangible assets | 28.08M | 23.93M | 26.32M | 28.71M | 44.93M |
| Other current assets | 44.07M | 34.87M | 24.30M | 21.92M | 101.34M |
| Total liab | 3012.61M | 2376.95M | 1888.91M | 1867.96M | 1878.37M |
| Total stockholder equity | -2076.58M | -1467.90M | -1354.26M | -1254.62M | -870.41M |
| Other current liab | 214.06M | 140.28M | 122.97M | 94.36M | 113.31M |
| Common stock | 0.20M | 0.20M | 0.18M | 0.16M | 0.15M |
| Capital stock | 0.20M | 0.20M | 0.18M | 0.16M | 0.15M |
| Retained earnings | -3821.19M | -3096.26M | -2560.50M | -1918.15M | -1436.97M |
| Other liab | - | - | - | 26.64M | 22.07M |
| Other assets | 140.75M | - | - | 140.81M | 33.03M |
| Cash | 570.12M | 681.10M | 375.94M | 376.69M | 393.77M |
| Total current liabilities | 287.97M | 154.40M | 143.84M | 117.75M | 130.13M |
| Current deferred revenue | 20.27M | 14.60M | 6.10M | 8.16M | - |
| Net debt | 2158.61M | 1049.48M | 1363.90M | 1346.88M | 1332.40M |
| Short term debt | 17.41M | 4.51M | 4.13M | 3.67M | 4.94M |
| Short long term debt total | 2728.72M | 1730.58M | 1739.84M | 1723.56M | 1726.17M |
| Other stockholder equity | 1734.37M | 1628.15M | 1206.03M | 663.70M | 566.53M |
| Property plant equipment | - | - | - | 14.57M | 45.97M |
| Total current assets | 753.68M | 720.69M | 477.59M | 505.20M | 839.71M |
| Long term investments | 79.97M | 143.75M | - | 43.65M | 49.15M |
| Net tangible assets | - | - | - | -1284.92M | -915.35M |
| Short term investments | 17.36M | 0.00M | 58.95M | 95.23M | 442.89M |
| Net receivables | 139.44M | 4.72M | 1.75M | 17.08M | 19.75M |
| Long term debt | 1852.47M | 1721.38M | 1726.73M | 1707.62M | 1703.81M |
| Inventory | 26.75M | 0.00M | 16.65M | 37.93M | -68.90M |
| Accounts payable | 36.23M | 9.62M | 10.65M | 11.56M | 11.88M |
| Noncontrolling interest in consolidated entity | - | - | - | 11.28M | 3.41M |
| Accumulated other comprehensive income | 0.01M | 0.01M | 0.03M | -0.33M | -0.13M |
| Common stock total equity | - | - | - | 0.16M | 0.15M |
| Retained earnings total equity | - | - | - | -1918.15M | -1436.97M |
| Treasury stock | - | - | - | -275.00M | -275.00M |
| Non currrent assets other | -81.44M | 18.20M | 22.62M | 20.22M | 33.03M |
| Non current assets total | 41.59M | 198.65M | 68.79M | 117.84M | 173.08M |
| Capital lease obligations | 10.00M | 9.20M | 13.11M | 15.95M | 22.37M |
| Long term debt total | - | - | - | 1707.62M | 1703.81M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | -17.20M | 60.78M | 54.03M | 453.15M | -166.23M |
| Change to liabilities | - | - | - | 9.82M | 22.22M |
| Total cashflows from investing activities | -24.49M | 60.78M | 54.03M | 453.15M | -200.83M |
| Net borrowings | 116.00M | 476.58M | 0.00M | -20.49M | 1063.61M |
| Total cash from financing activities | 359.29M | 748.46M | 451.54M | -13.13M | 736.45M |
| Change to operating activities | - | - | - | -2.00M | 12.52M |
| Net income | -724.93M | -543.35M | -643.20M | -484.65M | -586.45M |
| Change in cash | -111.10M | 288.51M | -22.15M | 20.52M | 37.69M |
| Begin period cash flow | 683.24M | 394.73M | 416.88M | 396.37M | 358.68M |
| End period cash flow | 572.14M | 683.24M | 394.73M | 416.88M | 396.37M |
| Total cash from operating activities | -445.91M | -520.73M | -527.72M | -419.49M | -497.93M |
| Issuance of capital stock | 0.00M | 314.74M | 449.81M | 4.85M | 0.00M |
| Depreciation | 5.97M | 6.08M | 6.49M | 6.77M | 5.84M |
| Other cashflows from investing activities | -6.19M | -7.97M | -0.50M | 115.77M | -21.35M |
| Dividends paid | - | - | - | - | -3.82M |
| Change to inventory | -25.31M | 0.00M | -15.33M | - | - |
| Change to account receivables | -134.72M | -2.97M | 15.33M | 15.17M | -19.75M |
| Sale purchase of stock | -48.28M | -7.53M | -6.88M | -1.56M | -204.75M |
| Other cashflows from financing activities | -12.08M | -35.34M | 8.61M | 4.06M | 1065.31M |
| Change to netincome | - | - | - | 112.72M | 111.13M |
| Capital expenditures | 1.10M | 0.93M | 1.31M | 6.32M | 48.25M |
| Cash flows other operating | - | - | - | -72.72M | -56.47M |
| Cash and cash equivalents changes | - | - | - | 20.52M | 37.69M |
| Change in working capital | -51.06M | 32.04M | 5.06M | 28.08M | -4.40M |
| Stock based compensation | 133.02M | 95.80M | 115.02M | 91.56M | 99.50M |
| Other non cash items | 191.09M | -111.30M | 103.93M | -61.25M | 18.50M |
| Free cash flow | -447.01M | -521.66M | -529.03M | -425.81M | -546.18M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| BBIO BridgeBio Pharma Inc |
3.75 5.31% |
74.48 | - | - | 29.41 | 123.68 | 32.15 | -9.40 |
| NVO Novo Nordisk A/S |
0.80 2.03% |
39.94 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
19.54 3.62% |
559.54 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
93.31 11.40% |
912.08 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for the treatment of molybdenum cofactor deficiency under the NULIBRY brand name; and low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 clinical stage or the treatment of children with achondroplasia and hypochondroplasia. It also develops Encaleret, an oral small molecule, negative allosteric modulator of the calcium sensing receptor, which is in phase 3 clinical study for the treatment of Autosomal Dominant Hypocalcemia Type 1(ADH1) and Chronic Hypoparathyroidism (CHP); BBP-418, an investigational, orally administered, and small molecule therapy that is in phase 3 clinical study for the treatment of LGMD2I; and BBP-812, an investigational adeno-associated virus (AAV) gene therapy for Canavan disease. In addition, the company engages in developing products for mendelian, oncology, and gene therapy diseases. It has license and collaboration agreements with the Bayer Consumer Care AG, Alexion Pharma International Operations Limited Company, Leland Stanford Junior University, and Novartis International Pharmaceutical Ltd. BridgeBio Pharma, Inc. was founded in 2015 and is headquartered in Palo Alto, California.
| Name | Title | Year Born |
|---|---|---|
| Dr. Neil Kumar Ph.D. | Co-Founder, Pres, CEO & Director | 1979 |
| Dr. Charles J. Homcy M.D. | Co-Founder, Chairman of Pharmaceuticals & Independent Lead Director | 1948 |
| Dr. Brian C. Stephenson C.F.A., Ph.D. | CFO, Sec. & Principal Accounting Officer | 1981 |
| Dr. Richard H. Scheller Ph.D. | Chairman of R&D and Director | 1953 |
| Dr. Frank McCormick Ph.D. | Co-Founder & Chairman of Oncology | 1950 |
| Dr. Uma Sinha Ph.D. | Chief Scientific Officer | 1957 |
| Grace Rauh | VP of Communications | NA |
| Mr. Eli M. Wallace Ph.D. | Chief Scientific Officer of Oncology | 1967 |
| Dr. Thomas Trimarchi Ph.D. | Chief Product Officer | NA |
| Dr. Eric Michael David J.D., M.D., Ph.D. | Chief Exec. Officer of Gene Therapy | 1972 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.64%
Communication Services
-0.16%
Consumer Cyclical
-0.15%
Consumer Defensive
+0.32%
Energy
-0.06%
Financial Services
-0.57%
Financials
+2.59%
Healthcare
-1.23%
Industrials
-0.83%
Real Estate
-0.24%
Technology
-2.67%
Utilities
-0.22%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...